JPS5823618A - 精神分裂症を治療する組成物 - Google Patents

精神分裂症を治療する組成物

Info

Publication number
JPS5823618A
JPS5823618A JP57117908A JP11790882A JPS5823618A JP S5823618 A JPS5823618 A JP S5823618A JP 57117908 A JP57117908 A JP 57117908A JP 11790882 A JP11790882 A JP 11790882A JP S5823618 A JPS5823618 A JP S5823618A
Authority
JP
Japan
Prior art keywords
guanfacine
composition
schizophrenia
patients
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57117908A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0251885B2 (enExample
Inventor
ミラン・マテチエク
カ−ル・テオハ−
ホルスト・クラインロ−ゲル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of JPS5823618A publication Critical patent/JPS5823618A/ja
Publication of JPH0251885B2 publication Critical patent/JPH0251885B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP57117908A 1981-07-09 1982-07-08 精神分裂症を治療する組成物 Granted JPS5823618A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH4512/81A CH649918A5 (de) 1981-07-09 1981-07-09 Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie.
CH4512/81-4 1981-07-09

Publications (2)

Publication Number Publication Date
JPS5823618A true JPS5823618A (ja) 1983-02-12
JPH0251885B2 JPH0251885B2 (enExample) 1990-11-08

Family

ID=4277474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57117908A Granted JPS5823618A (ja) 1981-07-09 1982-07-08 精神分裂症を治療する組成物

Country Status (7)

Country Link
US (1) US4404226A (enExample)
JP (1) JPS5823618A (enExample)
AU (1) AU563446B2 (enExample)
BE (1) BE893745A (enExample)
CH (1) CH649918A5 (enExample)
IT (1) IT1189308B (enExample)
PH (1) PH19374A (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0419654A (ja) * 1990-05-14 1992-01-23 Fuji Photo Film Co Ltd カラー現像主薬及び画像形成方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8401409D0 (sv) * 1984-03-14 1984-03-14 Astra Laekemedel Ab New pharmaceutical preparations and a new method of alleviation of pain
US4847300A (en) * 1986-11-07 1989-07-11 Yale University Use of alpha-2I selective adrenergic receptor agonists in memory enhancement
US5863934A (en) * 1995-09-21 1999-01-26 Amy F. T. Arnsten Use of lofexidine in the treatment of behavioral disorders
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
WO2007016284A2 (en) * 2005-07-28 2007-02-08 Shire Llc Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
WO2024246786A1 (en) * 2023-05-31 2024-12-05 Cumberland Pharmaceuticals Inc. Injectable guanfacine formulations and methods

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0419654A (ja) * 1990-05-14 1992-01-23 Fuji Photo Film Co Ltd カラー現像主薬及び画像形成方法

Also Published As

Publication number Publication date
BE893745A (fr) 1983-01-05
JPH0251885B2 (enExample) 1990-11-08
IT8248764A1 (it) 1984-01-07
AU563446B2 (en) 1987-07-09
CH649918A5 (de) 1985-06-28
IT8248764A0 (it) 1982-07-07
AU8571282A (en) 1983-01-13
US4404226A (en) 1983-09-13
IT1189308B (it) 1988-02-04
PH19374A (en) 1986-04-02

Similar Documents

Publication Publication Date Title
JP6334511B2 (ja) 新規方法
JP2818303B2 (ja) フィブロミアルギアの処置のためのセロトニンアンタゴニスト（５ｈｔ▲下３▼）の使用
ES3029536T3 (en) Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures
CA2626797C (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
DE69515038T2 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen
WO2006119958A2 (en) Use of flibanserin in the treatment of chronic pain
Stanley et al. Metoclopramide: antipsychotic efficacy of a drug lacking potency in receptor models
CN1185106A (zh) 咔唑化合物在治疗充血性心力衰竭中的应用
HU229150B1 (hu) Gyorsan ható szelektív szerotonin-újrafelvételt gátlókat alkalmazó eljárások nemi mûködési zavarok kezelésére
JPS59193821A (ja) 抗不安薬としてのフルオキセチンの使用法
JPS59112948A (ja) コレステロ−ルレベル低下剤
JPS5823618A (ja) 精神分裂症を治療する組成物
JPH05509293A (ja) 不整脈および発作の治療における５―ｈｔ４受容体拮抗剤の使用
KR930007252B1 (ko) 우울증 치료용 약학조성물
JP2717844B2 (ja) 新規な治療用医薬組成物
IL43820A (en) Pharmacological preparations for the treatment of deformed disabled, containing symptomatic aminophytic bronchodilators
Chouinard et al. Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac C capsule
ES2326078T3 (es) Medicamento destinado al sindrome de la disfuncion de integracion.
HUP0200501A2 (en) Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for treating sleep apnoea
US6372763B1 (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI)
JP2002541190A (ja) 気分障害治療用医薬を製造するためのオサネタントの使用
Akhtar et al. Local Anesthetic Drugs Used In Dentistry
JP2024529777A (ja) ＡＲＮｉとカルシウムイオンアンタゴニストとの医薬組成物および応用
JPH0393719A (ja) セルトラリンからなる薬物依存症治療剤
JPH05504957A (ja) 療法―抵抗性精神分裂症治療用医薬